31 results about "Disorders skin" patented technology

The invention relates to kits and methods for assessing skin health for a human and the human's susceptibility to skin disorders. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated disclosed herein and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.

Sets of genes are identified that show modulated activity in hyperpigmented sun-exposed (HE) and non-hyperpigmented sun-exposed (NHE) skin, when compared to non-hyperpigmented non-exposed (NHNE) skin. The modulated sets of genes reveal important information about the genetic changes that take place in skin as a result of environmental exposure and damage. The modulated sets of genes may be used to fabricate custom DNA microarrays for evaluating patients with skin diseases or disorders. The microarrays may also be used to screen new substances for treating skin diseases and disorders. The modulated gene sets, and substances that target them, may also be used to develop therapies for individuals who suffer from hypopigmentation, such as those with Fitzpatrick type I skin or vitiligo.

A lens for use on a device to assist in the phototherapeutic treatment of skin disorders where the device includes a housing having an interior containing a source of ultra-violet radiation or being adapted to receive ultra-violet radiation from an external source. The lens comprises a sheet-like structure releasably securable to the housing and for assisting in the direction of ultra-violet radiation from the housing to a desired skin surface. The lens has an upper surface and a lower surface with the upper surface generally adjacent to the interior of the housing. The lens further includes a plurality of generally hollow conical protrusions having upper and lower ends. The protrusions are situated on the lower surface of the lens such that when the lens is secured to the housing ultra-violet radiation is diverted outwardly through the lower ends of the protrusions.

The invention discloses essential oil for preventing and repairing skin barrier injury. The essential oil comprises the following components in percent by weight: 1.0 to 50 percent of camellia seed oil, 2.0 to 20 percent of plant oil, 0.5 to 5 percent of a relieving agent, 0.05 to 5 percent of a stabilizer, and the balance of synthetic oil. The essential oil contains rich various functional components; as all the components are harmonious with one another and synergistically affected, the essential oil can prevent skin barrier injury, and promote the repair process of skin barrier injury, andhas a good anti-allergy effect on sensitive skin with the disordered skin barrier function; in addition, the essential oil dost not contain emulgators or essence components, thereby avoiding an excessburden on skin.

Pro-apoptotic agents such as ligands and agonists of agonistic TRAIL receptors can induce or increase apoptosis of cells that cause fibrosis and underlying diseases such as liver, pancreatic, lung and skin diseases characterized by fibrosis, cirrhosis, or complications thereof. The compositions and methods can be used to selectively remove activated hepatic stellate cells (HSCs), the originators of liver fibrosis and cirrhosis, and activated pancreatic stellate cells (PSCs), the originators of pancreas fibrosis and pancreatitis, and can be effective to reduce or prevent further chronic fibrosis by simultaneously reducing multiple fibrosis-associated molecules secreted or induced by such activated stellate cells. The compositions are typically effective to target agonistic TRAIL receptors such as TRAIL-R1 / DR4 and TRAIL-R2 / DR5 that are selectively expressed in activated HSCs and PSCs in physiological conditions. Ligands and agonists that can be used to target agonistic TRAIL receptors include, but are not limited to, TRAIL-R1 / DR4 and / or TRAIL-R2 / DR5 agonists.

The present invention provides a method for the treatment of ocular or dermal diseases and / or conditions, e.g. an aqueous deficient dry eye state, uveitis or phacoanaphylactic endophthalmitis in an eye, or balanitis, psoriasis, or atopic dermatitis of the skin, said method comprising administering, topically to the eye or the skin, a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula:wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, e.g. a C2 to C6 polymethylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage, R is R is —N═C(NR3R4)(NR5R6) orNR7[(NR3R4)C═NR5], i.e. guanidines or—N═C(R8)(NR9R10), i.e. amidines wherein R3-R7 10 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4 or R4 and R5 or R5 and R7 or R3 and R7, or R9 and R10, together may be —CH2—CH2— or —CH2—CH2—CH2— and R2 is selected from the group consisting of hydroxyl, lower alkyl and hydroxyl-substituted lower alkyl and R2 is selected from the group consisting of hydroxy and lower alkyl.

The invention relates to an application of recombinant humanized collagen and a related composition and a preparation method thereof. Specifically, the invention provides the application of the recombinant humanized collagen in preparation of a product for preventing and / or treating allergic skin diseases (especially eczema), and also provides the composition containing the recombinant humanized collagen and the preparation method thereof. Experiments prove that the recombinant humanized collagen can effectively relieve skin redness and swelling, erythema, edema, pruritus and inflammatory response caused by eczema and can restore the skin gloss, and compared with a pure recombinant humanized collagen aqueous solution, the composition containing the recombinant humanized collagen can more quickly relieve eczema symptoms.

The invention discloses an externally applied medicine for treating skin disease and application thereof. The medicine consists of an active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient is a mixture of diflorasone and adapalene, or a mixture of diflorasone and acitretin, or a mixture of diflorasone, adapalene and acitretin. The invention overcomes the defects of poor treatment effect and high side effect of single medication, and the diflorasone and the adapalene or / and the acitretin are compounded to form the compound externally applied medicine. The preparation can be prepared into externally applied formulations in different forms; and due to synergic and complementary effects of medicines, the compound externally applied medicine has high treatment effect, lightens the adverse reaction of the patient in clinical application, has an obvious treatment effect on skin disease, and is easily accepted by the patient.

The invention discloses repairing cream. The cream is prepared by mixing deionized water, glycerin, betaine, 1,3-propanediol, a polyacrylate cross-linked polymer-6, plant squalane, phytosteryl / octyldodecyl lauroyl glutamate, poly(dimethylsiloxane), an Olea europaea fruit unsaponifiable matter, octadecyl 3-hydroxy-11-oxoolean-12-en-29-oate, tocopheryl acetate, natto gum, ectoine, 1,2-pentanediol, fucose, carboxymethyl chitosan, a shaddock fruit extract product, ceramide 3, 3-[2-(ethylhexyl)oxyl]-1,2-propandiol, and other components. Glucocorticoids and antibiotics are not contained, the productcan be used for gradually alleviating and improving symptoms of eczematoid dermatitis excited by glucocorticoid without recurrence, the product can adjust function of macrophage and neurotransmitter,inhibit inactivation of Na+ / K+-ATPase induced by hormone, reverse dryness, tightness, pruritus, papule, redness and other disorder skin problems in a short time, and mitigate pain of patients.

In some aspects, the present disclosure provides methods for identifying a disease in an epithelial tissue of a subject. Methods for identifying a disease in an epithelial tissue comprise the generation of a depth profile of the epithelial tissue using signals generated from the tissue by pulses of light directed towards a surface of the epithelial tissue. In some aspects, the present disclosure provides apparatuses consistent with the methods herein.

A unique garment designed to aid healing of minor skin ailments such as diaper rash. A urine absorbent, air flow permeable undergarment (1) may contain a barrier (4) to absorb urine and even an open back (5) such as for example a cutout in the back portion (3) a garment that may maximize airflow to the buttocks and groin. In some embodiments, a garment may not be a diaper and may not be designed to contain multiple urinations. In some embodiments, such as in a reusable form, the garment may be designed with a disposable pad capable of containing one or more urinations, then the disposable pad may be replaced. In yet another embodiment, a disposable garment may be provided so that after urination, the entire garment may be thrown away.

Compounds of formula (I) as human cytidine triphosphate synthase 1 (CTPS1) inhibitors for the treatment of prolifera-tive diseases, such as e.g. cancer, such as e.g. leukemia and lymphoma, e.g. inflammatory skin diseases such as psoriasis, or e.g. multiple sclerosis. The present description discloses the synthesis and characterisa-tion of exemplary compounds as well as pharmacological data thereof (e.g. pages 64 to 80; examples; biological examples 1 and 2; e.g. compounds P140, P231 to P263; tables 1 to 10). Specific examples are e.g.: N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonami-N do) pyrimidin-4-yl)tetrahydro-2H-pyran-4-carboxamide (Formula (II)), or 1-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)-N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)cyclohexane-1-carboxamide (Formula (III)).

The invention discloses a medicine application device for skin diseases. The device comprises a shell, connection bands, a control panel, a controller, a heater and silicone pads. The connection bandsare arranged at the two sides of the shell, each connection band is provided with a clamping groove and a buckle, the clamping grooves and the buckles are pasted to the connection bands, and the control panel is arranged at the upper side of the shell; the heater is arranged at the lower side of the shell, the controller is arranged at the inner side of the shell, and the controller is connectedto the heater through a wire; a lithium battery is arranged at the right side of the controller and connected to the controller through a wire, and the silicone pads are pasted to the inner sides of the connection bands. When the medicine application device is used, a medicine application patch is heated through the heater, the infected part can be well treated, the medicine effect of the medicineapplication patch is improved, convenience is provided for application of people, the connection bands are in contact with the body of a patient through the silicone pads, in the treatment process, the comfort feel is brought to the patient, and the device is suitable for application and popularization.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases / disorders and rheumatic diseases / disorders.

The present disclosure provides, inter alia, treating and / or preventing skin diseases and disorders and symptoms thereof, using recombinant LEKTI domains and microbes genetically modified to express one or more LEKTI protein domains encoded by one or more SPINK genes. In certain embodiments, compositions, methods, and kits are provided comprising recombinant LEKTI domains and microbes genetically modified to express one or more LEKTI protein domains encoded by one or more SPINK genes.

The invention relates to kits and methods for assessing skin health for a human and the human's susceptibility to skin disorders. The methods involve assessing occurrence in the human's genome of one or more polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated disclosed herein and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods.

The invention relates to a skin antibacterial solution for treating intractable skin disease and a preparation method thereof. The skin bacteriostatic solution is prepared from the following raw materials in parts by weight: 2 to 3 parts of polyhexamethylene guanidine, 4 to 6 parts of zaocys, 4 to 6 parts of raw radix rehmanniae, 4 to 6 parts of cortex dictamni, 4 to 6 parts of fructus kochiae, 4to 6 parts of flos carthami, 7 to 8 parts of radix salviae miltiorrhizae, 4 to 6 parts of radix astragali seu hedysari, 4 to 6 parts of pericarpium zanthoxyli, 240 to 260 parts of alcohol, 4 to 6 parts of menthol and 690 to 710 parts of water. According to the skin antibacterial solution disclosed by the invention, the functions of skin sterilization and itching relieving can be achieved, and thedamage to skin is reduced; meanwhile, skin moisture can be supplemented, and the effects of beautifying and whitening the skin can be achieved.

A medical applicator for skin diseases is characterized in that it comprises a pair of upper back supports (1), two pairs of front and rear ropes (2) connected to the upper back supports (1), and lower drug supports (3) connected to the other ends of the two pairs of front and rear ropes (2), wherein a whole formed by the upper back supports (1), the two pairs of front and rear ropes (2), and thelower drug supports (3) is of a horizontal V-shaped projection shape. The upper back supports (1) are the supporting points for the downward forces of the ropes (2); the ropes (2) are made of flexiblematerials, and the tightness control thereof is performed by a tightness adjusting mechanism (P); drugs capable of withstanding compression are arranged on the lower drug supports (3); the whole formed by the upper back supports (1), the two pairs of front and rear ropes (2), and the lower drug supports (3), of the horizontal V-shaped projection shape, is located on the skin between the two shoulders and the two legs of a patient (R), and it is in an open state for the body's overall treatment needs. When the medical applicator is used, the drugs capable of withstanding compression are arranged on the lower drug supports (3) and the upper back supports (1) are allowed to rest on the shoulders of the patient (R) so that the lower drug supports (3) can always be in a downward pressure state.

The invention discloses a pharmaceutical application of rhein as an S100A8 inhibitor in inflammatory diseases. The invention determines that rhein can be specifically combined with S100A8 protein, so that the level of inflammatory cytokines in an imiquimod-induced inflammatory skin disease model is reduced, and the inflammatory performance of skin is relieved. The invention suggests that rhein as a specific inhibitor of S100A8 has a potential therapeutic effect in S100A 8-related diseases such as inflammatory diseases.

Disclosed herein are methods and compositions for treatment of skin disorders and diseases using botulinum toxin targeted to nerve ganglia. It has been unexpectedly found that botulinum neurotoxin (BoNT) can decrease the severity of numerous skin disorders by application to nerve ganglia including but not limited to the parasympathetic, sympathetic, and sensory ganglia